Abstract:Protein kinases play pivotal roles in various biological functions, influencing cell differentiation, promoting survival, and regulating the cell cycle. The disruption of protein kinase activity is intricately linked to pathways in tumor development. This manuscript explores the transformative impact of protein kinase inhibitors on cancer therapy, particularly their efficacy in cases driven by targeted mutations. Focusing on key tyrosine kinase inhibitors (TKIs) like Bcr-Abl, Epidermal Growth Factor Receptor (EGFR), and Vascular Endothelial Growth Factor Receptor (VEGFR), it targets critical kinase families in cancer progression. Clinical trial details of these TKIs offer insights into their therapeutic potentials. Learning from FDA-approved kinase inhibitors, the review dissects trends in kinase drug development since imatinib's paradigm-shifting approval in 2001. TKIs have evolved into pivotal drugs, extending beyond oncology. Ongoing clinical trials explore novel kinase targets, revealing the vast potential within the human kinome. The manuscript provides a detailed analysis of advancements until 2022, discussing the roles of specific oncogenic protein kinases in cancer development and carcinogenesis. Our exploration on PubMed for relevant and significant TKIs undergoing pre-FDA approval phase III clinical trials enriches the discussion with valuable findings. While kinase inhibitors exhibit lower toxicity than traditional chemotherapy in cancer treatment, challenges like resistance and side effects emphasize the necessity of understanding resistance mechanisms, prompting the development of novel inhibitors like osimertinib targeting specific mutant proteins. The review advocates thorough research on effective combination therapies, highlighting the future development of more selective RTKIs to optimize patient-specific cancer treatment and reduce adverse events.

Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives

Kinase-targeted cancer therapies: progress, challenges and future directions

Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors

FDA-approved small molecule kinase inhibitors for cancer treatment (2001-2015): Medical indication, structural optimization, and binding mode Part I

Trends in kinase drug discovery: targets, indications and inhibitor design

Kinase Inhibitors FDA-Approved 2018-2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities

Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases.

Emerging Roles of Targeted Small Molecule Protein-Tyrosine Kinase Inhibitors in Cancer Therapy

Advances in Cancer Therapy: A Comprehensive Review of CDK and EGFR Inhibitors

Targeting cancer with small molecule kinase inhibitors

Recent Advances in Multi-target Drugs Targeting Protein Kinases and Histone Deacetylases in Cancer Therapy

PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.

Recent developments in receptor tyrosine kinase inhibitors: A promising mainstay in targeted cancer therapy

Dual-target Kinase Drug Design: Current Strategies and Future Directions in Cancer Therapy

The Progress of Tyrosine kinase Inhibitors in Cancer Therapy

Targeting Protein Kinases Benefits Cancer Immunotherapy.

An Overview of Kinase Downregulators and Recent Advances in Discovery Approaches.

Tyrosine kinase inhibitors: a clinical perspective

Recent Advances in the Discovery of Multitargeted Tyrosine Kinase Inhibitors As Anticancer Agents

Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives